SALE 🔍
KLOW (BPC-157 + GHK-Cu + TB-500 + KPV)

KLOW (BPC-157 + GHK-Cu + TB-500 + KPV)

A four-component lyophilized blend of BPC-157, GHK-Cu, TB-500 and KPV
BlendLyophilized powder

Price range: $120.00 through $1,056.00

Ships from lot 2026/02 · 99.4 % purity · Krause Analytical See the COA

UPS Ground $9.95. Free at $150. Orders before 2 pm ET ship the same business day.

Also available in the Pro Series.Its own lot. Its own certificate.
See KLOW (BPC-157 + GHK-Cu + TB-500 + KPV) – Pro
Sign in to get a restock email

Out of stock. Members get one email when it's back.

Ships from Austin, TexasUnited States only
Tested by an outside labNever in-house
Every lot publishedIncluding rejected lots
Same-day dispatchOn orders before 2pm ET
SKU: N/A Category:
BATCH
VERIFICATION
LOT NUMBER
2026/02
IDENTITY
Confirmed
CHROMATOGRAPHIC PURITY
99.4 %
NET CONTENT — BPC-157
9.20 mg
Analytical characterization

Every result against its specification.

Lot 2026/02 · Krause Analytical · reported 19 May 2026 . The bar shows where the reported result falls against Astramide’s published release criterion. The notch marks the criterion.
Within criterion Above criterion Not on this COA
Test
Method
Criterion
Result
Result vs criterion
Status
Identity
HPLC-UV-MS
Mass spectral match to the labelled compound
Confirmed
WITHIN SPEC
Chromatographic purity
HPLC-UV/MS
at or above 98.0%
99.4 %
95 at or above 98.0% 100
WITHIN SPEC
Net content — BPC-157
HPLC-UV-MS
9.20 mg
80 120
REPORTED
Net content — GHK-Cu
HPLC-UV-MS
32.5 mg
80 120
REPORTED
Net content — KPV
HPLC-UV-MS
6.32 mg
80 120
REPORTED
Net content — TB-500
HPLC-UV-MS
14.7 mg
80 120
REPORTED
Endotoxin
LAL, USP <85>
below 0.5 EU/mL
<0.5 EU/mL
WITHIN SPEC
Values are reported per vial or bottle unless otherwise noted. Every figure here is taken from the batch Certificate of Analysis and nothing else.
Certificate of Analysis
KLOW (BPC-157 + GHK-Cu + TB-500 + KPV) · Lot 2026/02 · Lab No. 205075
Download Full screen
Your browser cannot display the report inline. Open the PDF.
Krause Analytical · 3 pages · served inline, not a screenshot
Quick reference

How to read this report

Same six keys on every Astramide product page. Only the values change.
1Lot numberMatch it to the number printed on your product label. If they differ, this report is not for your product.
2IdentityMass spectrometry confirms the molecule is the one on the label. It conforms or it does not. There is no partial result.
3Chromatographic purityThe share of the material that is the target peptide. A purity figure quoted without a method is not a purity figure.
4Net contentHow much compound is in each vial or bottle, as measured by the laboratory. A different question from purity.
5EndotoxinMeasured against a ceiling, not a floor. Sensitivity differs by laboratory, so results are not compared across labs.
6Laboratory, method, dateWho ran it, on what instrument, and when. A report with no named laboratory or no date is not a report.
Molecular profile

KLOW (BPC-157 + GHK-Cu + TB-500 + KPV), in structural terms.

Sequence
BPC-157: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV) GHK-Cu: Gly-His-Lys, copper(II) complex TB-500: thymosin beta-4 peptide KPV: Lys-Pro-Val
Structure type
Blend
Primary molecular target
No single shared target. Published research has examined KPV uptake through the PepT1 transporter, actin monomer binding by thymosin beta-4, GHK copper complexes in extracellular matrix studies, and BPC-157 in a range of pre-clinical models.
Physical form
Lyophilized powder

KLOW is a lyophilized blend of four research peptides in one vial: BPC-157 (10 mg), GHK-Cu (50 mg), TB-500 (10 mg) and KPV (10 mg), 80 mg in total. BPC-157 is a 15-amino-acid peptide (GEPPPGKPADDAGLV, C62H98N16O22). GHK-Cu is the copper(II) complex of the tripeptide Gly-His-Lys. TB-500 is a thymosin beta-4 peptide. KPV is the tripeptide Lys-Pro-Val (C16H30N4O4). Each component is identified and measured separately on the certificate.

Research profile

Where KLOW (BPC-157 + GHK-Cu + TB-500 + KPV) appears in the literature.

Peptide Biology; Cell Biology; Cytoskeletal Biology; Extracellular Matrix Biology; Immunology
Research applications
  • Published studies have examined the individual components in:
  • BPC-157: pre-clinical models, including nervous system research
  • GHK-Cu: copper peptide and extracellular matrix research
  • TB-500 (thymosin beta-4): actin monomer binding and sequestration
  • KPV: PepT1 transport and NF-κB signaling
  • No published study has examined the four-component blend itself.
Experimental systems
  • Rodent models (BPC-157)
  • Fibroblast and extracellular matrix models (GHK-Cu)
  • Purified actin and cultured cell lines (thymosin beta-4)
  • Intestinal epithelial and immune cell lines (KPV)
Specific assays
  • Actin monomer binding assays
  • PepT1 uptake assays
  • NF-κB reporter assays
  • Extracellular matrix synthesis assays
  • HPLC and LC-MS analysis of blend composition
Measured endpoints
  • Actin monomer sequestration
  • PepT1-mediated peptide uptake
  • NF-κB activation
  • Extracellular matrix component synthesis
  • Content of each component in the blend
Pcs

Single Vial, 3-Pack, 6-Pack, Pack of 10
Mechanism and research context

What has been studied, and in what systems.

KLOW combines four peptides that have each been studied separately; no published study has examined the blend itself.

BPC-157 is a 15-residue peptide that has been examined in a range of pre-clinical models, including nervous system research (Vukojevic et al., 2022). GHK is a naturally occurring tripeptide that binds copper(II), and the GHK-copper complex has been studied in extracellular matrix and tissue remodeling research (Pickart et al., 2008).

Thymosin beta-4 binds and sequesters actin monomers (Yu et al., 1993). KPV, the C-terminal tripeptide of alpha-MSH, has been shown to enter intestinal epithelial and immune cells through the PepT1 transporter, and its effects on NF-κB signaling have been examined (Dalmasso et al., 2008).

These are published research systems. They do not describe approved clinical applications, and they do not establish efficacy or safety in humans.

Cited literature

Vukojevic J et al., 2022. Pentadecapeptide BPC 157 and the central nervous system. Neural Regen Res. PMID 34380875. https://pubmed.ncbi.nlm.nih.gov/34380875/
Pickart L et al., 2008. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed. PMID 18644225. https://pubmed.ncbi.nlm.nih.gov/18644225/
Yu FX et al., 1993. Thymosin beta 10 and thymosin beta 4 are both actin monomer sequestering proteins. J Biol Chem. PMID 8416954. https://pubmed.ncbi.nlm.nih.gov/8416954/
Dalmasso G et al., 2008. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. PMID 18061177. https://pubmed.ncbi.nlm.nih.gov/18061177/

Evidence level
Each component has its own pre-clinical literature, but no published study has examined the four-component blend. Statements on this page describe experimental systems for the individual components, not outcomes in humans.
Handling and storage
As supplied
Lyophilized powder in a sealed vial. Held in laboratory-rated freezers from arrival to shipment.
Storage
Store per the conditions printed on the vial label. Avoid heat, moisture and repeated temperature cycling.
Handling
For qualified professionals in controlled laboratory environments, following validated laboratory procedures.
Research Overview

Read our research write-up on this compound:

Frequently asked questions

About this compound and its batch data.

What is KLOW peptide?

KLOW is a lyophilized research blend of four peptides in one vial: BPC-157 (10 mg), GHK-Cu (50 mg), TB-500 (10 mg) and KPV (10 mg), 80 mg by label in total. The identity of each component is confirmed by mass spectrometry on the lot certificate. It is supplied for laboratory research use only.

What has KLOW been examined for in published research?

No published study has examined the four-component KLOW blend itself. Its components have been studied separately in pre-clinical work: BPC-157 (Vukojevic et al., 2022, PMID 34380875), GHK in tissue remodeling research (Pickart et al., 2008, PMID 18644225), beta-thymosins (Hannappel, 2007, PMID 17468232) and KPV in peptide transport models (Dalmasso et al., 2008, PMID 18061177). Astramide makes no claim about outcomes in humans.

What purity does the current KLOW lot reach?

Lot 2026/02 measured 99.4% chromatographic purity by HPLC-UV/MS, against a 98.0% specification. Identity of all four components was confirmed by mass spectral match. The lot was tested by Krause Analytical, laboratory reference 205075, reported 19 May 2026. Quote that reference to the laboratory to verify the certificate independently.

How much KLOW is in the vial?

Content is measured per component. Lot 2026/02: BPC-157 9.20 mg (92% of the 10 mg label), GHK-Cu 32.5 mg (65% of 50 mg), KPV 6.32 mg (63.2% of 10 mg) and TB-500 14.7 mg (147% of 10 mg). GHK-Cu and KPV are below label and TB-500 is above it. Astramide publishes the measured figures, not the label claim. Net content is a separate question from purity.

How is Astramide's KLOW tested?

Every lot is tested by an independent third-party laboratory. Lot 2026/02 was tested by Krause Analytical for identity and purity by HPLC-UV-MS, net content per component, and endotoxin by LAL to USP chapter 85, which returned below 0.5 EU/mL. Appearance is not reported on this certificate. Each method is explained in how Astramide tests every lot.

How should KLOW be stored for research use?

As supplied, the lyophilized powder should be held at -20°C and protected from light and moisture. Once reconstituted, store at 2 to 8°C and use within 14 to 30 days. Avoid repeated freeze-thaw cycles and follow the handling procedures appropriate to your laboratory.

What is the difference between research-grade and pharmaceutical-grade KLOW?

These are separate classifications. Research-grade material is supplied for laboratory research use only and is not intended for human or animal consumption. Pharmaceutical-grade is an FDA classification that applies to drugs manufactured for human use. Astramide supplies research-grade material only.

How is KLOW different from GLOW?

GLOW holds three peptides: BPC-157 (10 mg), GHK-Cu (50 mg) and TB-500 (10 mg), 70 mg by label. KLOW adds 10 mg of KPV, for 80 mg in total. Each blend is released under its own lot with its own certificate, so purity and content are reported separately for each.

Research use only

This product is intended strictly for in-vitro laboratory research conducted by qualified professionals. It is not intended for human or animal consumption, clinical use, or therapeutic application. The statements on this page have not been reviewed by the FDA. These research peptides are not intended to diagnose, treat, cure, or prevent any disease. Research Use Only.

COA library Every lot we have tested Search by batch number. Past lots stay published. How we test The analytical panel What each method measures and the criterion each lot must meet. Open Lab Send us your peptides Any vendor. Same lab. Your own Certificate of Analysis.
Ships from Austin, TexasUPS Ground, about 3 business days
United States onlyFree shipping at $150 and over
Tracked on every orderTracking number emailed when it ships
Replacement or store creditOn approved claims. See refund policy.

Related products